Growth Capital Firm Profile
In the last 3 years, Ampersand Capital Partners has acquired 5 companies. It has also invested in 9 others.
Ampersand Capital Partners’ most common sectors for investment arelife science (50%) and medical products (23%) . The Firm’s most common investment types include growth capital (35%) and buyout (lbo, mbo, mbi) (32%). In total, Ampersand Capital Partners has invested in 22 US states and 7 different countries. Its largest (disclosed) acquisition occurred in 2013 when it acquired BioClinica for $123M.
In the last 3 years, Ampersand Capital Partners has exited 11 companies. The Firm’s most common exit type is trade sale (75%). Ampersand Capital Partners’ largest (disclosed) exit occurred in 2008 when it sold Talecris Biotherapeutics Holdings Corp for $3.1B.
Join Mergr to view Ampersand Capital Partners’ full profile and discover more large growth capital firm investors just like it.
M&A Summary
-
M&A Total Activity118
- M&A Buy Activity67
- M&A Sell Activity51
- Total Sectors Invested 14
- Total Countries Invested 7
- M&A Buy/Sell Connections 56
- M&A Advisors 1